Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-BCMA-101 in Relapsed/Refractory Multiple Myeloma
NCT03288493Phase 2Terminated
- Sponsor
- Poseida Therapeutics
- Start
- Sep 2017
- Primary completion
- Apr 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of P-BCMA-101 in multiple myeloma (MM) (8 arms), sponsored by Poseida Therapeutics. Primary endpoints: Assess the Safety of P-BCMA-101 at Day 28, Maximum Tolerated Dose of P-BCMA-101 at Day 28 and 3 more. Started Sep 2017; status: terminated.
02
Drugs
P-BCMA-101
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03288493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288493.